← Back to Search

Other

ORIC-944 for Metastatic Prostate Cancer

Phase 1
Recruiting
Research Sponsored by ORIC Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with metastatic prostate cancer, including those with neuroendocrine prostate cancer (NEPC) and/or small cell features
ECOG performance status of 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Study Summary

This trial is testing a new drug to treat prostate cancer that has spread. They are testing to see what dose is safe and effective.

Who is the study for?
This trial is for men with metastatic prostate cancer who've had a bilateral orchiectomy or are on GnRH analogues. They must have progressed after treatment with certain androgen receptor antagonists and can't have had more than two chemo treatments in the mCRPC setting. Participants need to show disease progression, be able to undergo biopsies, have an ECOG status of 0 or 1, and adequate organ function.Check my eligibility
What is being tested?
The study aims to determine the optimal dose of ORIC-944 that patients can tolerate and its preliminary effectiveness against metastatic prostate cancer. It includes those with neuroendocrine features who've progressed despite previous therapies.See study design
What are the potential side effects?
While specific side effects of ORIC-944 aren't listed here, common ones for similar drugs include fatigue, nausea, changes in blood counts leading to increased infection risk or bleeding problems, hormonal imbalances, liver issues, and potential heart complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have prostate cancer that has spread, including types like NEPC.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I have had surgery to remove both testicles or am willing to continue treatment to keep my testosterone low.
Select...
My cancer is getting worse, shown by higher PSA levels or new bone/soft tissue issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Apparent plasma terminal elimination half-life (t1/2)
Area under the curve (AUC)
Maximum plasma concentration (Cmax)
+2 more
Secondary outcome measures
Clinical benefit rate (CBR)
Duration of response (DOR)
Objective response rate (ORR)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment1 Intervention
ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles

Find a Location

Who is running the clinical trial?

ORIC PharmaceuticalsLead Sponsor
7 Previous Clinical Trials
667 Total Patients Enrolled
Pratik S. Multani, MDStudy DirectorORIC Pharmaceuticals
3 Previous Clinical Trials
229 Total Patients Enrolled

Media Library

ORIC-944 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05413421 — Phase 1
Prostate Cancer Research Study Groups: Dose Escalation
Prostate Cancer Clinical Trial 2023: ORIC-944 Highlights & Side Effects. Trial Name: NCT05413421 — Phase 1
ORIC-944 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05413421 — Phase 1
~14 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top